BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37260707)

  • 1. Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients.
    Li X; Yi Y; Wu T; Chen N; Gu X; Xiang L; Jiang Z; Li J; Jin H
    Front Cell Infect Microbiol; 2023; 13():1170748. PubMed ID: 37260707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Intestinal Flora and Serum Metabolites in Lung Cancer.
    Chen S; Gui R; Zhou XH; Zhang JH; Jiang HY; Liu HT; Fu YF
    Front Cell Infect Microbiol; 2022; 12():885093. PubMed ID: 35586253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker.
    Wang S; He T; Wang H
    J Pharm Biomed Anal; 2024 Feb; 239():115869. PubMed ID: 38064771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.
    Tan Y; Yin P; Tang L; Xing W; Huang Q; Cao D; Zhao X; Wang W; Lu X; Xu Z; Wang H; Xu G
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.010694. PubMed ID: 22084000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
    Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Wu H; Zheng X; Pan T; Yang X; Chen X; Zhang B; Peng L; Xie C
    Int J Cancer; 2022 Oct; 151(8):1321-1334. PubMed ID: 35579980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
    Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma.
    Hou G; Xu W; Ding D; Tian T; Liu G; Yang Y; Liu H; Zhou W
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2321-2330. PubMed ID: 36208127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
    Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
    Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.
    Cao H; Huang H; Xu W; Chen D; Yu J; Li J; Li L
    Anal Chim Acta; 2011 Apr; 691(1-2):68-75. PubMed ID: 21458633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
    Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
    J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.